Description: Assembly Biosciences, Inc. provides development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences, Inc. in July, 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.
Home Page: www.assemblybio.com
ASMB Technical Analysis
331 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
833 509 4583
Officers
| Name | Title |
|---|---|
| Dr. John G. McHutchison A.O., FRACP, M.D. | CEO & Director |
| Mr. Jason A. Okazaki | COO & Pres |
| Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer |
| Dr. Uri A. Lopatin M.D. | Co-Founder and Clinical & Scientific Advisor |
| Dr. Adam Zlotnick | Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board |
| Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief HR Officer |
| Dr. Richard J. Colonno | Sr. Advisor |
| Dr. Tharaknath Rao | Head of Microbiome Clinical Devel. & Sr. VP |
| Ms. Michele Anderson | Chief Devel. Officer |
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5573 |
| Price-to-Sales TTM: | 10.1459 |
| IPO Date: | 2010-12-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 102 |